Abstracts tagged "Access to care"

Abstract Number: 1706 • ACR Convergence 2025
Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Ekemini Ogbu¹, Angela Migowa², Rashmi Sahay¹, Dhriti Sharma¹, Patricia Vega-Fernandez¹, Michael Henrickson¹, Evans Omalla³, Ayodele Faleye⁴, Wafa Hamdi⁵ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Aga Khan University Medical College East Africa, Nairobi, Kenya, ³Pediatric Society of the African League Against Rheumatism, Nairobi, Kenya, ⁴Lagos state university teaching hospital Ikeja, Lagos, Lagos, Nigeria, ⁵Kassab Institute, Faculty of Medicine of Tunis UR¹⁷SP⁰⁴, Tunis El Manar Univeristy, MANOUBA, Tunisia
Background/Purpose: Timely diagnosis of children, adolescents and young adults with rheumatologic disorders remains a global challenge especially in lower resource countries and areas (LRCs). There…
Abstract Number: 1067 • ACR Convergence 2025
Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
Karen Lin¹, Yuhan Ma¹, Simrat Morris² and Kristina Ciaglia³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern Medical Center and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Delays in diagnosis and treatment of pediatric localized scleroderma (LS) are common due to the under-recognition at initial presentation. While previous studies on pediatric…
Abstract Number: 0228 • ACR Convergence 2025
Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
Laura Nichols¹ and Steven Taylor², ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, CO
Background/Purpose: In the context of the rheumatology workforce shortage, eConsultation holds significant potential to address some challenges through supporting primary care providers in managing rheumatologic…
Abstract Number: 2680 • ACR Convergence 2025
High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Anna Costello¹, Rui Xiao¹, Jahan Jazayeri¹, Timothy Brandon¹, Xuemei Zhang¹, Irit Rasooly¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy and improves outcomes, yet JIA patients often experience circuitous pathways to diagnosis.…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 1705 • ACR Convergence 2025
Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions
Haelynn Gim¹, Leah Santacroce², Rebecca Summit³, Karli Retzel⁴, Virginia Bills⁴, Nancy Shadick³, Sara Schoenfeld⁵ and Candace Feldman², ¹Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham & Women's Hospital, Boston, ⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Adverse social determinants of health, or social risk factors (e.g., housing instability, food insecurity), contribute to disparities in rheumatic disease care and outcomes. Understanding…
Abstract Number: 1064 • ACR Convergence 2025
Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Hayley M Lynch¹, Jordan E. Roberts¹ and James N. Jarvis², ¹Seattle Children's Hospital/UW, Seattle, WA, ²University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Several studies detail a higher prevalence and severity of juvenile idiopathic arthritis (JIA) in Indigenous North American (INA) children compared to the general population.…
Abstract Number: 0223 • ACR Convergence 2025
Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Gopisree Peringeth¹, Benedict Wu¹, Shudan Wang², Beth McLellan³, Clement Tagoe⁴ and Jeanie Lee¹, ¹Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY
Background/Purpose: Collagen vascular diseases (CVD) often present with skin manifestations, but it is not always clear whether these changes are directly related to the underlying…
Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Manush Sondhi¹, Bhavik Bansal², Hemant Khandelia¹, Jiha Lee³, Sebastian E Sattui⁴, Siddharth Singh⁵ and Namrata Singh⁶, ¹University of Washington, Seattle, WA, ²UT Southwestern Medical Center, Dallas, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵University of California San Diego, San Diego, CA, ⁶University of Washington, Bellevue, WA
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Kuan-Tung Lin¹, Yue Hao², Mai Abdelnabi² and Wai-Hang Jackie Lam², ¹North East Medical Services, San Mateo, CA, ²North East Medical Services, San Francisco, CA
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…
Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Kimberly Cabrera¹, Priscilla Calvache², Lillian Mendez³, Giselle Morales⁴ and Jillian Rose-Smith², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Patient Advocate, Carteret, NJ, ⁴Hospital for Special Surgery, Glendale, NY
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
Abstract Number: 2586 • ACR Convergence 2025
Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Qiping Xu¹, Joan Bathon² and Yiming Luo², ¹Mayo Clinic, Mankato, ²Columbia University, NEW YORK, NY
Background/Purpose: The HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions. The 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout…
Abstract Number: 1981 • ACR Convergence 2025
High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education
Kami Roake¹, Natalie Morlan¹, Stephanie Lim¹, Jennifer Giles¹, Anthony Minjarez², Grant Cannon³, Nadia Grant⁴, Vivianne Allsop⁵, Miranda Jensen¹, Madeline O'Sullivan¹, Christopher Ching¹, Michael Bessen¹, Javier Rios⁶ and Jessica A. Walsh⁷, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, ⁵University of Utah, South Jordan, UT, ⁶University of Utah Health, Salt Lake City, UT, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Patient education is critical for managing rheumatic diseases. Rheumatology clinic pharmacists are well-positioned to assess and address gaps in patients’ understanding of their medications.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].